Now that it has won a bidding war for heart devices maker Guidant Corp. with a $27 billion offer, Boston Scientific Corp. faces its biggest challenge ever — making the deal work while it wrestles with its own mounting product problems.

The 27-year-old Massachusetts company owes much of its growth to successfully bringing newly acquired medical devices companies into the fold while managing risks in an industry notorious for product recalls and patent disputes.